Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension.

29 The Freedom C2 trial failed to reach statistical significance on its 6MWD primary endpoint with a median improvement of 10 m. 30 Both studies missed on secondary endpoints which included change in Borg Dyspnea Score rating, trough walk at Week 11, change in Dyspnea Fatigue Index, change in NYHA functional class, time to clinical worsening (as defined by death, transplant, atrial septostomy, hospitalization due to PAH or at least a 20% decrease in six-minute walk and initiation of another approved PAH therapy), and PAH signs and symptoms.

also in 6,035 other papers